Background Some recent studies have challenged the direction of causality for the association between cannabis use and psychotic disorder, suggesting that cannabis use initiation is explained by common genetic variants associated with risk of schizophrenia.
Introduction
Cannabis is used by some 200 million people worldwide, and its use and potency have increased in many countries [1] [2] [3] . Prospective epidemiological studies 4 , as well as biological investigations 5 , demonstrate a causal link between cannabis use and psychotic disorder. Recent evidence has confirmed a) a dose-response association with the highest odds of psychotic disorder in the heaviest cannabis users 6 and b) that high potency cannabis carries the greatest risk for psychotic disorder 7 . Indeed, daily cannabis use and use of high potency types have been linked to variation in the incidence of psychotic disorder across Europe 6 .
A recent study 8 showed that individuals with a family history of schizophrenia who develop a cannabis induced psychotic disorder, are especially likely to transition to schizophrenia. However, not all heavy cannabis users develop a psychotic disorder in the first place, and it remains unclear which genetic factors influence individual vulnerability to the psychotogenic effects of cannabis use.
Patterns of cannabis use such as lifetime cannabis use (never/ever used) and Cannabis Use Disorder (CUD) are influenced by genetic factors 9, 10 . Twin heritability reaches 45% for lifetime cannabis use and 51% to 70% for CUD 11, 12 . Genome wide Association Studies (GWAS) have also shown a significant genetic correlation between lifetime cannabis use and CUD on the one hand, and schizophrenia on the other 13 . Moreover, polygenic risk scores for schizophrenia (SZ PRS) have been reported to explain a small but significant proportion of the variance in lifetime cannabis use, quantity of cannabis used 14 and CUD 13 .
Mendelian Randomization (MR) studies have investigated if the reported genetic association between cannabis use phenotypes and schizophrenia results from a causal relationship between the two or from genetic pleiotropy; findings have been contradictory [15] [16] [17] . In the most recent study, Pasman et al 17 , used data from a large GWAS of cannabis use initiation to perform a bi-directional two sample MR analysis. In contrast to Vaucher et al 15 , they suggest a causal positive association of schizophrenia genes on cannabis initiation but not vice versa.
However, so far MR studies have only been able to explore a causal association between schizophrenia genes and cannabis use initiation rather than with those patterns of heavy cannabis use shown to impact on risk of psychotic disorder.
Therefore, using detailed data on pattern of cannabis use and GWAS data from a large multisite study, we aimed to test: 1) if SZ PRS predict cannabis initiation and/or patterns of cannabis use in population controls and first episode psychosis patients; 2) the individual and combined effects of SZ PRS and cannabis use on the risk of psychotic disorder and 3) if adding SZ PRS data to information on patterns of cannabis use improves the identification of those heavy cannabis users who will develop psychotic disorder.
Methods and materials
This paper derives from analyses of the EUGEI first episode case-control samples recruited between 1/5/2010 and 1/4/2015 in 17 catchment areas in England, France, the Netherlands, Italy, Spain and Brazil 18 .
Participants:
Cases: Patients presenting with their first episode of psychosis (FEPp) were identified by trained researchers who carried out regular checks across the 17 catchment area Mental Health Services. FEPp were included if a) age 18-64 years and b) resident within the study areas at the time of their first presentation, and received a diagnosis of psychosis (ICD-10 F20-33); further details are provided in the supplementary methods and in our recent publication 7 . Using the Operational Criteria Checklist algorithm 19, 20 , all cases interviewed received a research-based diagnosis. FEPs were excluded if a) previously treated for psychosis, b) they met criteria for organic psychosis (ICD-10: F09), or for a diagnosis of transient psychotic symptoms resulting from acute intoxication (ICD-10: F1X.5).
Controls: Random and Quota sampling strategies were adopted to guide the recruitment of controls from each of the sites. The most accurate local demographic data available were used to set quotas for controls to ensure the samples' representativeness of each catchment area's population at risk (see supplementary material). Controls were excluded if they had received a diagnosis of, and/or treatment for, psychotic disorder.
All participants provided informed, written consent. Ethical approval was provided by relevant research ethics committees in each of the study sites.
Measures of cannabis use
Data on patterns of cannabis use were collected using the modified Cannabis Experience Questionnaire further updated (CEQ EU-GEI ) 7 . None of the materials we used for the participants recruitment referred to cannabis or to its potential role as a risk factor for psychotic disorder. Participants were asked if they had ever used cannabis. If yes, they were asked to answer questions about their pattern of use, including the type of cannabis allowing the participants to report the "street" name, in the original language, of the cannabis they used with no reference to its potency.
We used measures of cannabis use that, in an independent sample, we reported 21 to increase the ORs for Psychotic Disorder: I) Age at first use of cannabis; II) lifetime frequency of use and III) the potency of the cannabis used. The latter was estimated, as described in Di Forti et al 7 using the EMCDDA 2016 report 22 and additional National published data on the concentration (%) of Tetrahydrocannabinol (THC) expected in the different types of cannabis available across Europe 22,23-30 (see supplementary material).
We also kept the variable "lifetime" ever cannabis use Yes/No to be able to compare our findings to the existing literature on the genetics of cannabis initiation 17 . Finally, we used the lifetime frequency of use and the cannabis potency variables to build the ""frequency-type composite cannabis use measure" that we previously tested 21 and replicated 5 to be a strong predictor of psychotic disorder. The "frequency-type" composite cannabis use measure includes 7 scores associated with a steady (from 0 to 6) increase in the OR for psychotic disorder 7, 21 : never used cannabis= 0; rare use of low potency cannabis (THC<10%)=1; rare use of high potency cannabis (THC=>10%)=2; use>than once a week of low potency cannabis (THC<10%)=3; use>than once a week of low potency cannabis (THC=>10%)=4; daily use of low potency cannabis (THC<10%)=5; daily use of high potency cannabis (THC=>10%)=6.
Genotyping
Samples were genotyped at the MRC Centre for Neuropsychiatric Genetics and Genomics in Cardiff (UK) using a custom Illumina HumanCoreExome-24 BeadChip genotyping array covering 570,038 genetic variants. To identify ethnic groups, we combined our dataset with the 1000 Genome Project (1000G), phase 3 and performed Principal Component Analysis on the overlapping SNPs. We then used the first two principal components to carry out 4-means clustering which identified the main study ethnic ancestry groups: African, European and Asian (Figure 1) . For example, individuals of European ancestry were defined as having PC values within 6 standard deviations from the mean PC of the EUR in 1000G, and retained for the downstream analyses.
Statistical Analysis
Polygenic risk scores (PRS) for schizophrenia (SZ PRS) were generated using PRSice from the summary results of the PGC analysis of schizophrenia, wave 2 31 . Clumping was performed to obtain SNPs in approximate linkage disequilibrium with an r 2 < 0.25 within a 250 kb window. PRS were calculated, separately for each of the three ancestry populations, at P-value thresholds of 0.05 31 . Then, each PRS was standardised (std_PRS) to mean of 0 and standard deviation of 1, excluding the MHC region. 32 . In STATA 15 we also calculated SZ PRS quintiles.
Adjusted logistic regression models were run to estimate: 1) if SCZ PRS predicted life time cannabis use and/or pattern of cannabis use and 2) the independent and combined effect of the selected measures of cannabis use, and the SZ PRS on the ORs for psychotic disorder. We fitted interaction terms to the logistic models and used likelihood ratio tests, to test if SZ PRS modify the effect of 1) the individual measures of cannabis use and 2) the "frequency-type composite cannabis use measure on the ORs for psychotic disorder. All regression models were adjusted for: 10 PCs, sites, age, sex and tobacco smoking as defined in our previous publication 7 (0=never smoked or <=10 cigarettes x day; 1= 11 cigarettes or more x day). In STATA 15 we used the "marginplot" command to display graphically the average predicted probability (y=axis) of being a case over increasing values of SZ PRS (x=axis) across different levels of exposures to cannabis use (i.e. frequency-type composite cannabis use measure).
Finally, the STATA 15 lroc command was used to assess the discriminatory ability (correctly classify case_control status) of some of the models tested.
Results
We approached 1519 patients FEP patients; 356 (23%) refused to participate, 19 (1%) could not consent because of language barriers and 14 (0.9%) were excluded as they did not meet the age inclusion criteria. Patients who refused to participate were older, more likely to be women and of European ancestry (supplementary methods).
1130 FEPp and 1499 population controls consented to take part. DNA samples were successfully collected from N=2190 participants out of the total N=2629 recruited (83%); DNA was extracted from blood (N=1857) or saliva (N=312).
The GWAS call rate of 98% (N=2125) resulted in a total sample with available genetic data to build the SZ PRS of FEPp=999 and controls=1147. Using the PCs approach described in the methods we calculated the Nagelkerke R 2 by the SZ PRS in each of our main Ethnic Ancestry groups: African (R 2 =0.03%; p=0.437; Controls N=301; FEPp N=402), European (R 2 =6.3%; p=5.15E-14; Controls N=787; FEPp N=492) and Others (R 2 =5.2%; p=1.03E-08; Controls N=59; FEPp N=105).
These differences in R 2 across the 3 main ethnic groups reflect the over-representation of individuals of European Ancestry in the PGC2 training sample used to calculate the SZ PRS and are consistent with previous reports 33 . Therefore, we restricted the working sample to those of white European Ancestry (supplementary methods flow chart). As shown in Figure 2 the SZ PRS was on average higher in FEPp than in controls (FEPp 
Proportion of the variance explained between cases and controls by patterns of cannabis use and SZ PRS
A model including the SZ PRS, 10 PCs plus age, sex and sites explained R 2 =11.3% (R 2 -Diff: p<0.001) of the variance between cases and controls. A model including age, sex, sites, tobacco smoking and daily use of cannabis explained R 2 = 15% (R 2 -Diff: p<0.001), which was not increased by adding age at first cannabis use, R 2 =15.7% (R 2 -Diff: p=0.285). In contrast, adding data on the potency of the cannabis used to the model explained a greater proportion of the variance R 2 =17.2% (R 2 -Diff: p=0.01), which further increased to 19.2% when we first only added to the model the 10 PCs, and then to R 2 =23.0% (R 2 -Diff: p<0.001) when we also added the SZ PRS (Figure 3) . Furthermore, ROC analyses indicated that the model only with SZ PRS, 10 PCs, age, sex and sites correctly classified 68.3% of cases, with a positive predictive value, PPV=55.2% and a negative predictive value, NPV=65.4%. This improved to 74.8% correctly classified cases, with a PPV=69.1% and NPV=75.3% for the model adding to SZ PRS, 10 PCs, age, sex, site both information on daily frequency of use and on the potency of the cannabis used.
In our control sample alone, SZ PRS and 10 PCs explained a non-significant proportion of the variance between those who never used cannabis and a) having tried it at least once (lifetime use R 2 =1.9%; p=0.334), b) having started at age 15 or younger (R 2 =2.3%; p=0.557), c) having used it daily (R 2 =1.3%; p=0.678) and d) using high potency types (R 2 =2%; p=0.063).
Does SZ PRS predict cannabis initiation and/or patterns of cannabis use?
Regression adjusted for age, sex, tobacco smoking, sites and for the 10 PCs showed that SZ PRS did not predict cannabis initiation (life time cannabis use yes/no) or starting using it at age 15 or younger both in controls (Life time cannabis use: b=0.027; p=0.51; age at 1 st use: b= 0.012; p=0.55) and in FEPp (Life time cannabis use b=0.001, p=0.93; age at 1 st use: b= -0.007;p=0.78). SZ PRS did not explain how frequently controls (b=0.027; p=0.06) or FEPp (b=0.006; p=0.91) used cannabis even when we specifically compared never use with daily use (FEPp: b=-0.013; p=0.64; Controls: b=0.003; p=0.86). Finally, SZ PRS did not predict the type of cannabis used by controls (b = 0.032; p=0.31) or by FEPp (b= 0.005; p=0.89) (supplementary Figure 1) .
The independent and combined effect of SZ PRS and pattern of cannabis use on the

ORs for Psychotic Disorder
Adjusted Logistic regressions showed that SZ PRS 4 th quintile (OR=1.7; 95% CI 1.24-3.23; p=0.002) and 5 th quintile (OR=3.2; 95% CI 2.11-5.68); p<0.001) were associated with an increase in ORs for psychotic disorder compared to the 3 rd quintile (middle quintile) after controlling for age at 1 st cannabis use, frequency of use and the potency of the cannabis used. Lifetime cannabis use (crude OR=1.3, 95% CI 1.01 -1.703, p<0.050; adjusted OR=0.81, 95% CI 0.59-1.01;p=0.082) and age at 1 st use=<15 years old (crude OR=2.0, 95% CI 1.44-2.97, p<0.001; adjusted OR=1.1, 95% CI 0.67-1.68,p=0.771) were no longer associated with an increase in the ORs for psychotic disorder after taking into account frequency of use and cannabis potency. On the contrary, using cannabis daily and using high potency increased the ORs for psychotic disorder independently of each other, of age at 1 st use and also of SZ qPRS. Table 2 The ORs for psychotic disorder of daily cannabis users (Interaction: Daily use*SZ qPRS: LR chi2 (4) =0.97;p=0.91) or users of high potency types (Interaction: Cannabis Potency*SZ qPRS: LR chi2(4) = 4.98;p=0.289) compared to never users were not modified by SZ PRS quintiles (qPRS). Table 2 Those who used potent types of cannabis more than once a week, THC=>10%, (OR=2.5,95% CI 1.26-5.00, p=0.008) or used daily either low potency, THC<10% (OR=3.5; 95% CI 1.74-7.46, p=0.001) or high potency types (OR=5.4; 95% CI 3.21-10.63,p<0.001) had an increase in the ORs for psychotic disorder compared to never users, independently of their SZ PRS and after adjusting for age, sex, site, smoking status and 10PCS. Indeed, we plotted predictive margins to display if and how, the probability (Pr) of being a FEPp, varied, on average, with the increase in SZ PRS across each group of the frequency-type composite cannabis use measure Figure 4 . This showed that on average the probability (Pr) of being a FEPp progressively increased with the increase in SZ PRS across all the 7 groups of the frequency-type composite cannabis use measure. Daily users of high potency cannabis (THC=>10%) were the group with the highest Pr of being a FEPp at all level of SZ PRS, followed by daily users of THC<10% and weekly users of THC=>10%. The remaining 3 groups, never used and used rarely (i.e. less than weekly) either type of cannabis, showed a similar change in the Pr of being a FEPp with the increase in SZ PRS.
Finally, an adjusted regression model with a fitted interaction term between SZ PRS and the frequency-type composite cannabis use measure, both fitted as continuous variables, showed an independent effect of SZ PRS (OR=2.29; 95%CI 1.71-3.05) and of the frequency-type composite cannabis use measure (OR=1.32; 95% CI 1.22-1.44) on the OR for psychotic disorder, but only weak evidence of an interaction ("prs_std*Frequency_Type" OR=0.91, 95% CI 0.84-0.99; p=0.033; Likelihood ratio test LR chi2(1) = 4.50; p= 0.033) .
Heavy cannabis user-only analyses:
Within the sample of cannabis users only, adjusted logistic regression indicated a trend for increase in ORs for Psychotic Disorder in daily cannabis users in the 4 th (OR=2.6; 95% CI 0.91-9.84;p=0.06) and 5 th (OR=3.1; 95% CI 0.74-11.9; p=0.08) SZ PRS quintiles compared to those in the 3 rd quintiles. The same pattern was shown among users of high potency cannabis with those in the 4 th SZ PRS quintile (OR=2.7; 95%CI1.2-6.1; p=0.01) and in the 5 th quintile (OR=3.6; 95%CI 1.4-9.0; p=0.006), compared to the 3 rd one, reaching a significant increase in the ORs for Psychotic Disorder ( 
Discussion
Our findings are the first providing estimates of risk for psychotic disorder by joint modelling the severity of cannabis use and common variant genetic liability to schizophrenia.
Indeed and in contrast with the reports from two of the MR studies 16, 17 that suggest a causal relationship between schizophrenia genes and cannabis initiation, we found that SZ PRS did not predict individuals' propensity to try cannabis, age at first use, frequency of use, or the potency of the cannabis used. All analyses took into account the effect of age, sex, study sites, tobacco smoking and 10PCs. These findings are consistent with a recent cross-sectional study, which tested gene-environment interaction between SZ PRS and regular cannabis use and showed no evidence of correlation between the two 34 .
Several large genetic studies have reported that SZ PRS explained around 1% or less of the variance in life-time cannabis use and or CUD 13, 14 . In our control sample we found that SZ PRS explained a similar, but non-significant proportion of the variance for all our measures of cannabis. The evidence that the genetics of cannabis use and schizophrenia overlap does not explain why only a minority of cannabis users, even of those using daily and using high potency types 7,21 develop a psychotic disorder. We addressed this question by testing for interaction between SCZ PRS and measures of cannabis use, controlling for the confounding effect of study sites, age, sex, tobacco smoking and 10PCs. Firstly in our sample, SZ PRS, daily cannabis use and use of high potency independently from each other increase the ORs for psychotic disorders. Hence, daily users of high potency cannabis had an over 5-fold increase in the OR for psychotic disorder compared to never users even when controlling for SZ PRS. Furthermore, we found no evidence that SZ PRS modified the effect of lifetime cannabis use, age at 1 st use, frequency of use and type of potency used on the OR for psychotic disorder. Though, we report weak evidence that SZ PRS might modify the effect of the frequency-type composite cannabis use measure on the OR for psychotic disorder.
In Figure 4 we report that on average the probability (Pr) of suffering from a psychotic disorder progressively increased with the increase in SZ PRS across all the seven groups of the frequency-type composite cannabis use measure. In line with the existing evidence 6 , those who used high potency cannabis (THC=>10%) daily were the group with the highest Pr of being a FEPp at all levels of SZ PRS, followed by daily users of THC<10% and weekly users of THC=>10%. However, we found no evidence of a positive interaction between the frequency-type composite cannabis use measure and the SZ PRS.
Our data indicate that SZ PRS and heavy cannabis use (e.g. daily use, use of high potency types) exert effects independent from each other on the OR for psychotic disorder. Moreover, to date the analyses testing for overlap, correlation and direction of causality between the genetics of Schizophrenia and the genetics of cannabis use have relied on data from the PGC 2 SZ GWAS. The latter is likely to have included more cannabis users among the cases than the controls, as it has been consistently reported that patients with schizophrenia have higher rates of cannabis use than the general population 36, 37 . This could partially explain the reported shared genetics and have confounded the findings suggesting a direction of causality from SZ genes to some cannabis use phenotypes.
Following from existing evidence that indicates individuals at high risk for psychotic disorder 38 and/or with a known family for psychosis 39 , are more vulnerable to the psychotogenic effect of cannabis use, we show that adding SZ PRS data to easily available socio-demographic information could improve the identification of those heavy cannabis users who are more likely to suffer from a psychotic disorder. Not all heavy cannabis users develop a psychotic disorder, though we have previously shown 5 that daily frequency of use and use of high potency cannabis account for a significant proportion of new cases of psychotic disorder across Europe. Therefore, beginning to identify a set of data, including genetic summary scores like SZ PRS, that more accurately classify those daily uses of high potency cannabis at risk of psychotic disorder, could have important public health implications.
Our findings need to be appraised in the context of our study's strengths and limitations.
For instance the study sample size, reduced to obtain a more ethnically homogenous population, might have affected the power to detect a significant interaction between the single categorical measures of cannabis use, daily use, age at first use and use of high potency and SZ PRS.
Another limitation may be the lack of biological measures validating our self reported data of cannabis use. Nevertheless, as we were interested not on the effect of recent use but on life time exposure, measures such as urine, blood or hair samples testing could not have validated history of use over previous years 40, 41 . Furthermore, studies that have collected both laboratory and self-reported information on cannabis use have shown both sets of data to be highly correlated 42 .
Our estimates of cannabis potency cannot account for differences in the THC% in individual samples. Our cut off of THC =10% is conservative and likely to have resulted in an underestimate of the effects of cannabis potency on the ORs for psychotic disorder.
Importantly, our study is the first to test the relationship between SZ PRS and use of high potency cannabis; the latter known to be increasing worldwide, and to be associated, with high rates of psychosis across Europe 7 . Moreover, in our previous paper we described a probabilistic sensitivity analyses, which showed that selection bias is unlikely to explain the reported findings on the strength of the impact of daily cannabis use and use of high potency on the ORs for psychotic disorder 7 .
Findings from first episode studies are a) less likely to be biased by illness course and less likely to produce recall bias than other study designs relying on history of exposure to environmental factors that is collected retrospectively as in prevalence samples 43 .
Finally, an important strength of our study lies in our control samples, which were recruited to represent the population at risk of each of the study sites catchment area 7, 18 . This was achieved by setting quotas based on the main socio-demographics of the populations at risk.
In conclusion, our findings suggest that despite reports of an overlap between the genetics of schizophrenia and of cannabis use, SZ PRS is far from explaining who is going to use cannabis and their pattern of use. At a time when cannabis use is increasing in popularity and becoming accessible even as a prescription drug, our study provides the first indication that using genetic data might become a tool to guide how much cannabis (and containing how much THC) an individual with a certain SZ PRS can safely use, and how likely they are to develop psychotic disorder if they use high potency cannabis daily. 
